|Original language||English (US)|
|Number of pages||2|
|Journal||American Journal of Psychiatry|
|State||Published - May 2021|
ASJC Scopus subject areas
- Psychiatry and Mental health
Access to Document
Other files and links
In: American Journal of Psychiatry, Vol. 178, No. 5, 05.2021, p. 381-382.
Research output: Contribution to journal › Comment/debate › peer-review
TY - JOUR
T1 - Electroconvulsive therapy is an essential procedure
AU - Maixner, Daniel F.
AU - Weiner, Richard
AU - Reti, Irving M.
AU - Hermida, Adriana P.
AU - Husain, Mustafa M.
AU - Larsen, Dane
AU - McDonald, William M.
N1 - Funding Information: Dr. Maixner has received research support for the clinical study of ketamine in depression and travel expenses for research development from the National Network ofDepressionCenters, andhe has received research funding from Neuronetics and St. Jude Medical. Dr. Reti has received grant support from the Brain and Behavior Research Foundation, the Dana Foundation, the U.S. Department of Defense, the Hope for Depression Research Foundation, NIH, the Patient-Centered Outcomes Research Institute, and the Simons Foundation for Autism Research Initiative, and he has had contracts with BrainsWay, John Wiley & Sons, and Neuronetics. Dr. Hermida has received grant support from the National Institute on Aging. Dr. Husain has received grant and/or research support from the BRAIN Initiative, NIMH, the National Institute on Aging, NIH, the National Institute of Neurological Disorders and Stroke, and the Stanley Foundation. Mr. Larsen serves as executive director of the National Network of Depression Centers. Dr. McDonald is a member of the APA Council on Research representing the practice of electroconvulsive and neuromodulation therapies; he receives compensation as chair of the data and safety monitoring board for the National Institute on Aging; he receives support from the Wounded Warrior Project as part of the Emory University Veterans Program; he receives royalties from Oxford University Press; he serves as a board member of Skyland Trail and 3Keys; he is a paid consultant for Signant Health and Parallel Georgia; and he has received funding from the J.B. Fuqua Foundation, Cervel Neurotherapeutics, Neuronetics, NeoSync, Soterix, and the Stanley Foundation. Dr. Weiner reports no financial relationships with commercial interests.
PY - 2021/5
Y1 - 2021/5
UR - http://www.scopus.com/inward/record.url?scp=85105841869&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105841869&partnerID=8YFLogxK
U2 - 10.1176/appi.ajp.2020.20111647
DO - 10.1176/appi.ajp.2020.20111647
M3 - Comment/debate
C2 - 33979536
AN - SCOPUS:85105841869
SN - 0002-953X
VL - 178
SP - 381
EP - 382
JO - American Journal of Psychiatry
JF - American Journal of Psychiatry
IS - 5